UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural ...

Eggs and embryos from people with polycystic ovary syndrome have altered patterns of so-called epigenetic tags, which could ...

The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of type-1 diabetes, hepatitis, ...

Specifically, the FDA removed the Risk Evaluation and Mitigation Strategy (REMS) program requirements from two BCMA-directed CAR T-cell therapies for multiple myeloma — ciltacabtagene autoleucel ...

FDA updates CAR T-cell therapy labels, easing monitoring requirements and expanding access for eligible patients in oncology.

A fertilized egg somehow manages to build skin, brain, and blood cells within days. But how? New tech called LoxCode is ...

Bristol Myers (BMY) receives FDA approval for label updates for Breyanzi and Abecma, that can ease access to the cancer cell ...

Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and ...

B ristol Myers Squibb (BMS) has announced that the US Food and Drug Administration (FDA) has given approval to label updates ...

Blue Label has a non-controlling 49.5% stake in Cell C, and is looking to get an additional 4.04% stake via The Prepaid Company (TPC) in order to get control of South Africa’s fourth-biggest ...

JSE-listed Blue Label on Friday said it is considering a possible restructure to facilitate a separation and potential future listing of Cell C on the JSE. The proposed restructure, with various ...